Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
TCRCure Biopharma Ltd.
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
TCR2 Therapeutics
TCR2 Therapeutics
City of Hope Medical Center
M.D. Anderson Cancer Center
Peking University
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
SCG Cell Therapy Pte. Ltd.
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
HRYZ Biotech Co.
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Herlev Hospital
Corregene Biotechnology Co., Ltd
National Institutes of Health Clinical Center (CC)
Shanghai 6th People's Hospital
Mie University
Immetacyte Ltd
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Zhejiang University
Sheba Medical Center
Mie University
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Sun Yat-sen University
National Institutes of Health Clinical Center (CC)
Herlev Hospital
Shenzhen Second People's Hospital